Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.
A phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (amsacrine, m-AMSA) was carried out in previously treated patients with advanced ovarian carcinoma. The dose of amsacrine was 90 mg/m2 every 3 weeks in 34 patients having received prior extensive chemotherapy and/or radiotherapy, and 120 mg/m2 in 5 patients who had previously only received moderate amounts of chemotherapy. Among patients evaluable for response the median number of courses was 3 (range 2-17). Two patients (5%) experienced complete response for 15+ months. Leucopenia was the most frequent toxic effect. WBC nadir was 2700/mm3 (range 1000-7300). Other toxic effects were of lesser significance and included thrombocytopenia, anemia, nausea and vomiting. It is concluded that amsacrine has only marginal activity in patients with previously treated ovarian carcinoma.
D000328:Adult; D000368:Aged; D000609:Aminoacridines / Q000008:administration & dosage* / Q000009:adverse effects; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine